1139717-76-2

Usage

Uses

Used in Organic Synthesis:
3-(4-methylpiperazin-1-yl)phenylboronic acid is used as a reagent for the synthesis of complex organic molecules, leveraging the phenylboronic acid group's ability to form stable complexes with diols, which is crucial in the construction of pharmaceutical and agrochemical compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-(4-methylpiperazin-1-yl)phenylboronic acid is utilized as a building block for the design of new drugs. The 4-methylpiperazin-1-yl group enhances the pharmacokinetic properties of pharmaceuticals, making 3-(4-methylpiperazin-1-yl)phenylboronic acid instrumental in the development of medications with improved efficacy and safety profiles.
Used in Pharmaceutical Development:
3-(4-methylpiperazin-1-yl)phenylboronic acid is employed as a key intermediate in the synthesis of pharmaceuticals, where its unique structural features contribute to the creation of novel therapeutic agents with potential applications across various medical disciplines.
Used in Agrochemical Synthesis:
3-(4-methylpiperazin-1-yl)phenylboronic acid also finds application in the agrochemical industry, where it is used as a reagent in the development of new pesticides and other agrochemical products, capitalizing on the phenylboronic acid group's reactivity and complex-forming properties with diols to create effective and targeted agrochemicals.

Upstream product

• 747413-17-8 1-bromo-3-(4-methylpiperazin-1-yl)benzene 
• 5419-55-6 Triisopropyl borate 
• 109-01-3 1-methyl-piperazine 
• 108-36-1 1,3-dibromobenzene 

Downstream Products

• 1350659-91-4 8-fluoro-4-[5-[3-(4-methylpiperazin-1-yl)phenoxy]pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1200126-42-6 3-(3-(4-methylpiperazin-1-yl)phenyl)-9H-pyrrolo[2,3-b:5,4-c′]-dipyridine-6-carbonitrile 

Relevant academic research and scientific papers

PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES

a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X and Y are independently NR5 or O; W and Z are independently a bond or (CH2)mCH(R7)(CH2)n; m=0-1, n=0-2; R is hydrogen or halogen; R1 and R2 are independently selected from hydrogen halogen, CF3, CN, OR8, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R3 is hydrogen, halogen, CF3, CN, OR8, SR8 or SO2R11; R4 is hydrogen, halogen, CF3, OR9, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R7 is hydrogen, C1-6 alkyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR9; R8 is hydrogen or C1-6 alkyl optionally substituted by fluorine, C1-6 alkoxy or NR9R10, R9 is hydrogen, C1-6 alkyl or C1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR8, NR9R10 Or OCF3; R10 is hydrogen, C1-6 alkyl, C1-6 alkenyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR8 or OCF3; or the groups R9 and R10 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR9, S and O; and R11 is C1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR8 is provided. The compounds are useful in treating amyloid related diseases.